<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39325692</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Continuous quality improvement with a two-step strategy effective for mass SARS-CoV-2 screening at the Tokyo 2020 Olympic and Paralympic Games.</ArticleTitle><Pagination><StartPage>e0304747</StartPage><MedlinePgn>e0304747</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0304747</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0304747</ELocationID><Abstract><AbstractText>The Tokyo 2020 Olympic and Paralympic Games (Games) were held during the height of the coronavirus disease 2019 (COVID-19) pandemic. To detect people infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) early enough to contain the spread and to facilitate the timely arrival of athletes at their game venues, all participating athletes staying in the Olympic Village (up to 14,000) were screened daily for the infection. Toward this aim, a two-step strategy was adopted comprising screening of self-collected saliva samples using a chemiluminescence enzyme immunoassay, followed by confirmatory testing using polymerase chain reaction. The testing system was integrated with an information management system covering all steps. To ensure the accuracy of the test results, rigorous quality assurance measures and monitoring of performance/specimen quality were implemented. A chronological chart analysis was implemented to monitor the holistic process and to give feedback to improve the sampling. Nearly all test results for 418,506 saliva samples were reported within 12 hours of sample collection, achieving the target mean turnaround time of 150 minutes for confirmatory testing. As a result, athlete activity and performance for the Games were ensured. The chronological chart confirmed that no athletes were withdrawn due to a false-positive result, and no infection clusters were identified among the athletes in the Olympic Village. In conclusion, continuous quality improvement as part of the two-step strategy for mass screening for COVID-19 contributed to the success of the Games during the pandemic. The quality practice, systems, and workflows described here may offer a model for future mass-gathering sporting events during similar major infectious disease epidemics.</AbstractText><CopyrightInformation>Copyright: © 2024 Miyachi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyachi</LastName><ForeName>Hayato</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5343-6751</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Clinical Laboratory Sciences, Nitobe Bunka College, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asai</LastName><ForeName>Satomi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4075-3141</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuroki</LastName><ForeName>Rika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>SRL Inc., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omi</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>SRL Inc., Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>H.U. Group Research Institute G.K., Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujirebio Inc., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikenoue</LastName><ForeName>Chiaki</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Field Epidemic Intelligence, Research and Professional Development, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimada</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Eco-Epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014041" MajorTopicYN="N" Type="Geographic">Tokyo</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="Y">Saliva</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="Y">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013177" MajorTopicYN="N">Sports</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056352" MajorTopicYN="N">Athletes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal’s policy and the authors of this manuscript have the following competing interests: For non-financial conflicts of interest, H.M., S.A., S.S., and C.I. have published several papers about COVID-19 and could have conflicts of interest among healthcare professionals. For financial conflicts of interest, H.M. was a consultant at SRL Laboratories and an adviser for the laboratory in the Olympic and Paralympic Village in Harumi, Tokyo, Japan. H.M. and S.A. were involved in the nationwide external quality assessment of SARS-CoV-2 nucleic acid tests, a project commissioned by the Ministry of Health, Labour and Welfare of Japan. S.A. contributed to studies on SARS-CoV-2 PCR tests developed by DENSO Corp. and KYORIN Pharm. Co., Ltd. that were financially supported by the Japan Agency for Medical Research and Development. R.K. and K.O. rendered laboratory service for athletes and team officials during the Tokyo 2020 Games as a commission project by the Tokyo Organizing Committee of the Olympic and Paralympic Games. S.S. and C. I. worked as staff members for Tokyo 2020 during the Tokyo 2020 Games. The authors report no other potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325692</ArticleId><ArticleId IdType="pmc">PMC11426491</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0304747</ArticleId><ArticleId IdType="pii">PONE-D-24-17763</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (2020). Rolling updates on coronavirus disease (COVID-19). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (Accessed on 27 Nov 2023).</Citation></Reference><Reference><Citation>Shimada S, Ikenoue C, Iwashita Y, Miyamoto T. Contributions of the Tokyo 2020 Infectious Diseases Control Centre in curbing SARS-CoV-2 spread during the Olympic and Paralympic Games. Br J Sports Med. 2023;57:6–7. doi: 10.1136/bjsports-2022-105691</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsports-2022-105691</ArticleId><ArticleId IdType="pubmed">36113974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota I, Shane PY, Teshima T. Logistic advantage of two-step screening strategy for SARS-CoV-2 at airport quarantine. Travel Med Infect Dis. 2021;43:102127. doi: 10.1016/j.tmaid.2021.102127</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102127</ArticleId><ArticleId IdType="pmc">PMC8220861</ArticleId><ArticleId IdType="pubmed">34174408</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota I, Shane PY, Okada K, Unoki Y, Yang Y, Inao T, et al.. Mass Screening of Asymptomatic Persons for Severe Acute Respiratory Syndrome Coronavirus 2 Using Saliva. Clin Infect Dis. 2021. Aug 273(3):e559–e565. doi: 10.1093/cid/ciaa1388</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1388</ArticleId><ArticleId IdType="pmc">PMC7543374</ArticleId><ArticleId IdType="pubmed">32976596</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota I, Shane PY, Okada K, Unoki Y, Yang Y, Iwasaki S, at al. A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study. Lancet Microbe. 2021. Aug2(8):e397–e404. doi: 10.1016/S2666-5247(21)00092-6 Epub 2021 May 19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00092-6</ArticleId><ArticleId IdType="pmc">PMC8133768</ArticleId><ArticleId IdType="pubmed">34031649</ArticleId></ArticleIdList></Reference><Reference><Citation>International Organization for Standardization. ISO/TS 5798; 2022. In vitro diagnostic test systems–Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods. Available from: https://www.iso.org/standard/81712.html (Accessed on 27 Nov 2023).</Citation></Reference><Reference><Citation>Asai S, Seki A, Akai Y, Tazawa H, Kakizoe H, Ravzanaaadii MA, et al.. Nationwide external quality assessment of SARS-CoV-2 nucleic acid amplification tests in Japan. Int J Infect Dis. 2022;115:86–92. doi: 10.1016/j.ijid.2021.11.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.022</ArticleId><ArticleId IdType="pmc">PMC8595969</ArticleId><ArticleId IdType="pubmed">34800690</ArticleId></ArticleIdList></Reference><Reference><Citation>ISO 15189:2022. Medical laboratories—Requirements for quality and competence. https://www.iso.org/standard/76677.html</Citation></Reference><Reference><Citation>Burke P. Tokyo 2020 did not result in increased COVID-19 cases in Japan IOC claims citing study. 31 Dec 2021. https://www.insidethegames.biz/articles/1117299/tokyo-2020-covid-cases-contained-ioc</Citation></Reference><Reference><Citation>Nishino T Obara K Nishida Y et al.. Large-scale international volleyball competition in "bubble" under the COVID-19 pandemic. Asia Pac J Sports Med Arthrosc Rehabil Technol. 202227:9–12. doi: 10.1016/j.asmart.2021.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.asmart.2021.12.001</ArticleId><ArticleId IdType="pmc">PMC8683270</ArticleId><ArticleId IdType="pubmed">34956838</ArticleId></ArticleIdList></Reference><Reference><Citation>Caniza H Forriol F Pangrazio O et al. Safety of international professional sports competitions during the COVID-19 pandemic: the association football experience. Sports Med. 202353:765–768. doi: 10.1007/s40279-022-01763-3. Epub 2022 Sep 27. PMID: 36167919</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514706</ArticleId><ArticleId IdType="pubmed">36167919</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Ai J, Bao J, Zhang W. Lessons learned from the COVID-19 control strategy of the XXXII Tokyo Summer Olympics and the XXIV Beijing Winter Olympics. Emerg Microbes Infect. 2022;11:1711–1716. doi: 10.1080/22221751.2022.2090859</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2090859</ArticleId><ArticleId IdType="pmc">PMC9258436</ArticleId><ArticleId IdType="pubmed">35726527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>